Roy van der Meel
Roy van der Meel is a biomedical engineer specialized in nanomedicine and RNA therapeutics. After obtaining a PhD from Utrecht University under guidance of prof. dr. Wim Hennink and prof. dr. Gert Storm, and a postdoc appointment at the University Medical Center Utrecht in prof. dr. Raymond Schiffelers’ lab, he secured Marie Skłodowska-Curie and Dutch Research Council (NWO) Veni funding to move to prof. dr. Pieter Cullis’ lab at the University of British Columbia in Vancouver, Canada. During his 3.5-year postdoctoral tenure, he gained extensive experience with developing lipid nanoparticle (LNP) technology that has enabled the approval of the first siRNA therapeutic Onpattro® and the COVID-19 mRNA vaccines. This included developing microfluidics-based LNP production methods and fundamental investigations into the LNPs’ self-assembly process. In 2019, he was recruited to Eindhoven University of Technology by prof. dr. Willem Mulder and appointed Assistant Professor in the Precision Medicine group. His current research is supported by NWO Vidi funding and focuses on establishing platform nanotechnology for delivering RNA therapeutics to specific immune cells and regulating the innate immune response. He has co-authored over 50 publications in leading nanotechnology-focused journals including Nature Nanotechnology, Nature Biomedical Engineering, and ACS Nano.